Lab Sciences
Top stories summarized by our editors
6/22/2017

An additional cell-culture manufacturing facility in Vacaville, Calif., will produce Genentech's Rituxan SC formulation for the treatment of B-cell non-Hodgkin lymphoma. The plant is part of an almost $300 million expansion project that will double production capacity.

More Summaries:
non-Hodgkin lymphoma
6/22/2017

The State Intellectual Property Office of China will award Intellia Therapeutics a patent for its CRISPR-Cas9 single-guide gene editing technology.

More Summaries:
Intellia Therapeutics, Intellia
6/21/2017

Cornea transplants treated with cytokines had a higher rate of graft survival than control corneas in a study involving mice reported in the journal Scientific Reports. "When we grafted the tissue that has been treated that way, active tolerance was developed, which leads to long-term acceptance of the corneal transplant and suppresses all the destructive sides of immunity," lead author Dr. Reza Dana said.

Full Story:
Optometry Today (UK)
6/21/2017

Dr. Matthew Kuehnert, former head of the CDC's Office of Blood, Organ and Other Tissue Safety, will serve as the medical director of the Musculoskeletal Transplant Foundation. "We are delighted that Dr. Kuehnert has chosen to join MTF and look forward to working with him to leverage his perspective and experience to advance the science of tissue transplantation, and to continue our focus on saving and healing the lives of people by providing the safest possible donated human tissue transplants," said MTF President and CEO Bruce Stroever.

6/21/2017

Mosquitoes carrying West Nile virus have been captured in Staten Island, and New York City health officials have outlined a vector-control plan that includes larvicide applications in marshes and areas with standing water. No cases of human infection were reported.

6/20/2017

US and Guatemalan researchers plan to examine babies with Zika virus infections in Guatemala for at least one year and compare them with youths younger than 5 to bolster understanding on how Zika affects neurological and neurodevelopmental growth and other pediatric health outcomes. Preliminary results from the study may be ready in one year.

More Summaries:
Guatemala, Zika
6/20/2017

Patients with relapsed or refractory diffuse large B-cell non-Hodgkin lymphoma had a 59% complete response rate and an 86% objective response rate after receiving JCAR017, a chimeric antigen receptor T-cell therapy, according to updated results from the Phase I TRANSCEND study presented at the International Conference on Malignant Lymphoma. "This is the first multicenter trial of a CD19-directed CAR T cell product with defined composition to deliver potent and durable responses in poor-prognosis subgroups," lead investigator Dr. Jeremy Abramson said.

Full Story:
Cure Today
6/20/2017

Tessa Therapeutics has signed a multiyear agreement with the Parker Institute for Cancer Immunotherapy to develop cell therapies and immuno-oncology combination drugs using Tessa's virus-specific T cell technology. Tessa has an ongoing late-stage study of TT10 for advanced nasopharyngeal carcinoma.

Full Story:
BioCentury
6/20/2017

The FDA accepted a new-drug application from Rigel Pharmaceuticals for Tavalisse, or fostamatinib disodium, an oral treatment for chronic or persistent immune thrombocytopenia.

6/20/2017

The anti-CD38 antibody daratumumab received FDA approval for use in combination with pomalidomide and dexamethasone as a third-line treatment for multiple myeloma. The drug was approved previously as a fourth-line treatment for certain patients.